Apple's iPhone Lost More Ground in China in Second Quarter
By Jiahui Huang
Apple's performance in China's smartphone market weakened further in the second quarter, hurt by rising popularity of local brands, preliminary data from a trio of industry trackers showed.
Apple fell out of a ranking of the top five shippers of smartphones in China, according to separate reports by Canalys and International Data Corp., while Counterpoint Research estimated that Apple's market share by sales contracted.
All three cited demand for local smartphones, led by Vivo, amid rising shipments overall. Huawei and Xiaomi's double-digit shipments growth also pressured the market share of Apple's, IDC data showed.
Counterpoint said Apple's market share by sales was 15.5% in the second quarter, down from 15.7% in the first quarter and 17.4% a year ago. Overall smartphone sales in China rose 6% from a year earlier, which "confirms the recovery theme emerging in the world's largest smartphone market," it added.
Canalys estimated that smartphone shipments in China rose 10% from a year ago to more than 70 million units in the second quarter, while IDC estimated shipments expanded by 8.9% to 71.6 million units.
Recovery was supported by "pent-up replacement needs" and a low base of comparison, IDC said.
Write to Jiahui Huang at jiahui.huang@wsj.com
(END) Dow Jones Newswires
July 26, 2024 05:36 ET (09:36 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks